First Patient Dosed in Pivotal Lung Cancer Trial, Shares Jump 10%
EIKN sits 24% above its 52-week low of $7.9 on light trading volume (0.1× avg).
Summary
Eikon Therapeutics dosed the first patient in the Phase 2/3 TeLuRide-008 registrational trial of EIK1001 for first-line stage 4 non-small cell lung cancer. This is the second registrational study for the drug, following the ongoing melanoma trial initiated last year. The milestone marks a concrete step toward a potential approval in a large indication, and the market is reacting with a 10% share price increase. The company's strong $596 million cash position provides ample runway to advance the program. Next catalysts include enrollment updates and eventual data readouts from both registrational trials.
At the time of this announcement, EIKN was trading at $9.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $530.6M. The 52-week trading range was $7.90 to $17.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.